Search

Metabolically healthy obesity (MHO) refers to obese individuals with a favorable metabolic profile, without severe metabolic abnormalities. This study aimed to investigate the potential of follistatin, a regulator of metabolic balance, as a biomarker to distinguish between metabolically healthy and unhealthy obesity. This cross-sectional study included 30 metabolically healthy and 32 metabolically unhealthy individuals with obesity. Blood samples were collected to measure the follistatin levels using an enzyme-linked immunosorbent assay (ELISA). While follistatin did not significantly differentiate between metabolically healthy (median 41.84 [IQR, 37.68 to 80.09]) and unhealthy (median 42.44 [IQR, 39.54 to 82.55]) individuals with obesity (p = 0.642), other biochemical markers, such as HDL cholesterol, triglycerides, C-peptide, and AST, showed significant differences between the two groups. Insulin was the most significant predictor of follistatin levels, with a coefficient of 0.903, followed by C-peptide, which exerted a negative influence at −0.624. Quantile regression analysis revealed nuanced associations between the follistatin levels and metabolic parameters in different quantiles. Although follistatin may not serve as a biomarker for identifying MHO and metabolically unhealthy obesity, understanding the underlying mechanisms that contribute to metabolic dysfunction could provide personalized strategies for managing obesity and preventing associated complications. [ABSTRACT FROM AUTHOR]

Introduction: It is the responsibility of the ethical committees to ensure that the studies carried out on volunteers are carried out in accordance with ethical rules. In this study, it is aimed to analyze the deficiencies in the 2018-2021 application forms of the Istanbul Haydarpaşa Numune Training and Research Hospital Clinical Research Ethics Committee. Methods: The number of applications and revisions, the quality and type of research, area of application and acceptance rate were analyzed retrospectively in the archives of the ethics committee, in 598 files that were finalized between January 2018 and December 2020. Results: In the examined period, the total number of applications has doubled as of the end of 2020 compared to January 2018 (131, 194 and 273 for the years 2018, 2019 and 2020, respectively), and almost all of the applications are non-pharmacologic clinical trials. Among these studies, the highest number of applications are individual research projects, and more than half of them are prospective (63.06%, 66.46% and 58.30%, respectively). The number of applications for which corrections were requested is 77 (58.77%), 107 (55.15%) and 107 (39.19%) according to years. Most of the corrections requested are method related. The highest increase in the number of revisions was in the misidentification of the research type (0.78%, 6.02% and 6.94% for 2018-2020, respectively). Discussion and Conclusion: It was determined that the researchers had difficulties in the study methodology, informed consent and preparation of the scientific basis. Planning periodical Good Clinical Practices (GCP) trainings on an institutional basis under the leadership of ethics committees and that the specialty students have completed their current GCP training before starting their specialty thesis studies will ensure that the research projects to be carried out will be of higher quality in terms of ethics and science [ABSTRACT FROM AUTHOR]

Introduction: Ehrlich-Ziehl-Neelsen (EZN) staining and culture methods are often used to diagnose tuberculosis. This study aimed to determine the acidfast bacteria (AFS) positivity rates in various clinical samples sent to our laboratory over five years and the growth and resistance rates in two different (solid and liquid) cultures and compare them with the data from Türkiye and the world., Materials and Methods: A total of 62.456 clinic samples were accepted in the microbiology laboratory between 2019 and 2024. The mycobacterial culture was performed by searching for acid-resistant bacilli microscopically and parallel inoculation media [solid Löwenstein-Jensen (L-J) and MGIT 960 liquid]. Those growing in the MGIT 960 system were identified using BD MGIT TBC Identification test kits that detect the MPT64 antigen. AFS and MPT64 antigenpositive samples were identified as Mycobacterium tuberculosis complex (MTBC) while AFS-positive samples and MPT64 antigen-negative results were classified as non-tuberculous mycobacteria (NTM). Drug susceptibility testing was performed with the BACTEC MGIT 960 SIRE kit. Susceptibility to NTM samples was not performed., Result: Out of a total of 120.829 samples, 95.101 were lung samples and 25.728 were extrapulmonary samples. AFS positivity was detected in 2961 (2.4%) samples. MTBC grew in 6854 (5.6%) samples, and NTM grew in 1506 (1.24%) samples. Contamination was detected in 7171 (5.9%) media. Two thousand one hundred and sixty-nine susceptibility tests were performed. Considering antibiotic resistance rates, isoniazid resistance was detected in 154 (7%), rifampicin resistance in 140 (6.4%), ethambutol resistance in 18 (0.8%), and streptomycin resistance in 120 (0.5%) samples. All four-drug resistance was observed in 91 (4.1%) samples. AFP positivity and resistance rates for rifampicin have decreased significantly, while there have been no significant changes in NTM rates over the years., Conclusions: When our data was determined, the sensitivity of microscopy was low. It is understood that mycobacterial culture and microscopy must be evaluated together to exclude tuberculosis infection. The high mycobacterial culture positivity rate, which is 5.6%, is due to the high number of follow-up patients and new referrals. It is seen that the change in sensitivity rates is due to the period of the COVID-19 epidemic, and it is similar to World Health Organization (WHO) data.